星空体育注册官网|正牌大公司

You Position: Home > Paper

Cost-utility analysis of 1-dose and 2-dose varicella attenuated live vaccine immunization strategies using a decision tree-Markov cohort model

( views:6, downloads:0 )

Author:: No author available

Journal Title:: Chinese Journal of Vaccines and Immunization

Issue:: 2

DOI:: 10.19914/j.CJVI.2024032

Key Word:: 水痘减毒活疫苗;成本效用分析;决策树-Markov模型;Varicella attenuated live vaccine;Cost-utility analysis;Decision tree-Markov model

Abstract： Objective To analyze the cost-utility of 1-dose and 2-dose varicella attenuated live vaccine(VarV)immunization strategies.Methods We constructed a cost-utility decision tree-Markov model of VarV immunization strategies for the 2022 Chinese birth cohort and estimated the cost and utility[Quality-adjusted life year(QALY)]of none,1-dose,and 2-dose immunization strategies.We determined incremental cost-utility ratios(ICURs)of 1-dose and 2-dose immunization strategies.Results Total cost of 0-dose,1-dose.,and 2-dose VarV vaccination strategies were 49 130.561,10 370.688,and 8 145.216 million yuan,respectively,yielding utilities of 738.414,740.135,and 740.231 million QALYs.ICURs for 1-dose and 2-dose vaccination strategies compared with no vaccination were-22 524.3 and-22 564.1 yuan per QALY.Univariate sensitivity analysis showed that discount rate,treatment costs for outpatients without complications,and utility value for outpatients with complications were the main parameters influencing ICUR.Conclusions Both 1-dose and 2-dose VarV immunization strategies had good cost-utility and would save money.

Reference

[1]何飞,马永法,顾春艳,等.2005-2021年盐都区水痘流行特征[J].2023,35(1).
[2]潘璠,金正格,王瑶,等.2005-2019年六安市疫苗针对传染病突发公共卫生事件流行特征分析[J].2021,(7).
[3]Zhang Zhujiazi,Suo Luodan,Pan Jingbin,etc.Two-dose varicella vaccine effectiveness in China: a meta-analysis and evidence quality assessment[J].2021,21(1).
[4]Bardach,A.,Cafferata,M.L.,Klein,K.,etc.Incidence and use of resources for chickenpox and herpes zoster in Latin America and the Caribbean - A systematic review and meta-analysis[J].2012,31(12).
[5]涂正波,徐群英,万刚凤,等.南昌市红谷滩新区水痘经济负担及疫苗免疫的成本效益分析[J].2019,(2).
[6]胡雅飞,黎春霞,林海江.浙江省台州市192例水痘病例经济负担调查[J].2022,37(3).
[7]Lara J,Wolfson,Vincent J,Daniels,Matthew,Pillsbury,etc.Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model.[J].2019,14(8).
[8]S, Feldman,L, Lott.Varicella in children with cancer: impact of antiviral therapy and prophylaxis.[J].1987,80(4).
[9]Xu, Yuyang,Liu, Yan,Zhang, Xiaoping,etc.Epidemiology of varicella and effectiveness of varicella vaccine in Hangzhou, China, 2019[J].2021,17(1).
[10]王洋,胡永玲,胡平.应用青岛市6-13岁人群病例对照研究评价水痘减毒活疫苗保护效果[J].2021,(1).
[11]Lenne X,Diez Domingo J,Gil A,etc.Economic evaluation of varicella vaccination in Spain: results from a dynamic model[J].2006,24(47/48).
[12]王嘉豪,张海军,方海.基于决策树-马尔可夫模型的轮状病毒疫苗纳入国家免疫规划的成本效益分析[J].2022,28(3).
[13]Bonanni P,Boccalini S,Bechini A,etc.Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases.[J].2008,26(44).
[14]Zafer,Kurug?l,?ule,G?k?e.Outbreak of varicella in preschool children despite one-dose vaccination.[J].2018,60(1).
[15]Andrea Horváth.Acceptance of varicella vaccination[J].2021,17(6).
[16]Saeko Morino,Keiko Tanaka-Taya,Hiroshi Satoh,etc.Descriptive epidemiology of varicella based on national surveillance data before and after the introduction of routine varicella vaccination with two doses in Japan, 2000–2017[J].2018,36(40).
[17]Oliver, Damm,Bernhard, Ultsch,Johannes, Horn,etc.Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.[J].2015,15.
[18]James Lopez,Bernal,Peter,Hobbelen,Gayatri,Amirthalingam.Burden of varicella complications in secondary care, England, 2004 to 2017.[J].2019,24(42).
[19]刘方珉,时黎明,姚烨,等.水痘疫苗纳入免疫规划对其发病率的影响[J].2023,35(7).
[20]Quinn, Helen E.,Gidding, Heather F.,Marshall, Helen S.,etc.Varicella vaccine effectiveness over 10 years in Australia; moderate protection from 1-dose program[J].2019,78(3).
[21]潘金仁,邓璇,何寒青.浙江省水痘病例经济负担和生命质量评估[J].2019,(5).
[22].Routine immunization services costs and financing in China, 2015[J].2018,36(21).
[23]胡倩倩,张倩,李媛秋,等.2020年中国1-14岁儿童水痘减毒活疫苗接种率调查[J].2022,28(2).
[24].Varicella in Poland: economic burden in children 1–12 years of age in Poland, 2010–2015[J].2018,18(1).
[25]Boot HJ,de Melker HE,Stolk EA,etc.Assessing the introduction of universal varicella vaccination in the Netherlands[J].2006,24(37/39).
[26]张夏晴,吕勇,王瑶,等.六安市2010-2022年水痘流行特征和水痘疫苗保护效果[J].2023,29(3).
[27]Hobbelen, Peter H. F.,Stowe, Julia,Amirthalingam, Gayatri,etc.The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013[J].2016,73(3).
[28]Domingo JD.,Ridao M.,Latour J.,etc.A cost benefit analysis of routine varicella vaccination in Spain[J].1999,17(11/12).
[29].Varicella and herpes zoster vaccines: WHO position paper, June 2014.[J].2014,89(25).
[30]Prymula, Roman,Povey, Michael,Brzostek, Jerzy,etc.Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries[J].2021,39(19).
[31]朱琳,韩一楠,杨月.中国幼托机构及中小学聚集性水痘疫情中疫苗保护效果的meta分析[J].2020,(16).